LivaNova and Verily in Research Agreement to Treat Depression

LivaNova has entered into a research partnership with Verily Life Sciences, an Alphabet company, to evaluate the effectiveness of Vagus Nerve Stimulation (VNS) therapy for Difficult to Treat Depression (DTD). The collaboration comes a few short months after London-based LivaNova ended its transcatheter mitral valve replacement (TMVR) program because of continued declines in revenue from its valve business. In the RECOVER clinical study, LivaNova and Verily aim to gather quantitative data on patient behavior using technology and analytics developed by Verily to further understand depressive episodes and a patient’s response to treatment. RECOVER clinical sites will have the ability to offer patients the Verily Study Watch, a wearable device designed to capture physiological and environmental data for clinical research, and a Verily mobile phone app. These complementary approaches are expected to help investigators better understand the impact of depression and its treatment on study participants’ lives in a more objective and multi-dimensional manner. “The goal of the RECOVER study is to assess how VNS Therapy can offer patients with DTD relief from their symptoms and improve their quality of life,” Damien McDonald, CEO of LivaNova, said in a release. “Through this collaboration with Verily, we can build on our work to study depression and better understand the complex elements that contr...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Digital Health Source Type: news